Inactive Instrument

Xbrane Biopharma AB Stock Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Xbrane Biopharma AB
Sales 2024 * 344M 31.64M Sales 2025 * 680M 62.65M Capitalization 331M 30.5M
Net income 2024 * -101M -9.3M Net income 2025 * 104M 9.58M EV / Sales 2024 * 0.56 x
Net cash position 2024 * 138M 12.75M Net Debt 2025 * 116M 10.66M EV / Sales 2025 * 0.66 x
P/E ratio 2024 *
-1.6 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.11%
More Fundamentals * Assessed data

Latest transcript on Xbrane Biopharma AB

Managers TitleAgeSince
Chief Executive Officer 44 14-12-31
Director of Finance/CFO 63 21-01-10
Chief Tech/Sci/R&D Officer 42 17-10-08
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Director/Board Member 70 14-12-31
Director/Board Member 53 19-12-31
More insiders
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company